CD3 × CD19 bispecific T-cell engager (specialist)
Blinatumomab
Brand names: Blincyto
Adult dose
Dose: 9–28 micrograms/day continuous IV infusion per protocol
Route: IV (continuous infusion)
Frequency: Continuous infusion in hospital
Clinical pearls
- NICE TA589 / TA665: relapsed/refractory Ph- B-cell ALL; MRD-positive ALL
- BSH ALL guidelines; ESMO
- Specialist haemato-oncology centre with CRS/ICANS expertise
Contraindications
- Active serious infection
- Hypersensitivity
Side effects
- Cytokine release syndrome
- ICANS / neurotoxicity
- Tumour lysis
- Cytopenias
- Infections
- Capillary leak
- Pancreatitis
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- FBC
- Cytokines
- ICE score
- Infections
- Pancreatic enzymes
Reference: BNF; NICE TA589; NICE TA665; BSH ALL; ESMO; SmPC; https://bnf.nice.org.uk/drugs/blinatumomab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158